Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | IGC |
---|---|---|
09:32 ET | 13215 | 0.4171 |
09:34 ET | 3719 | 0.439999 |
09:38 ET | 16356 | 0.4171 |
09:39 ET | 3667 | 0.4379 |
09:41 ET | 1529 | 0.419 |
09:45 ET | 1011 | 0.426751 |
09:54 ET | 292 | 0.4269 |
09:56 ET | 100 | 0.42685 |
09:57 ET | 110 | 0.433095 |
09:59 ET | 2650 | 0.4334 |
10:01 ET | 14968 | 0.43 |
10:03 ET | 100 | 0.43 |
10:06 ET | 1162 | 0.4352 |
10:08 ET | 400 | 0.4388 |
10:10 ET | 13653 | 0.43 |
10:12 ET | 100 | 0.427 |
10:24 ET | 500 | 0.43 |
10:26 ET | 1000 | 0.44 |
10:32 ET | 1352 | 0.4388 |
10:35 ET | 850 | 0.433501 |
10:48 ET | 500 | 0.4388 |
10:57 ET | 1000 | 0.4349 |
11:00 ET | 2203 | 0.427 |
11:04 ET | 1596 | 0.4271 |
11:08 ET | 1014 | 0.427 |
11:09 ET | 500 | 0.4216 |
11:11 ET | 650 | 0.427 |
11:13 ET | 150 | 0.421 |
11:15 ET | 907 | 0.42355 |
11:18 ET | 100 | 0.423549 |
11:20 ET | 12485 | 0.427 |
11:27 ET | 13500 | 0.42 |
11:31 ET | 12168 | 0.4273 |
11:54 ET | 147 | 0.421 |
11:58 ET | 1412 | 0.43 |
12:02 ET | 164 | 0.421 |
12:09 ET | 100 | 0.44 |
12:14 ET | 1262 | 0.421 |
12:21 ET | 2092 | 0.421 |
12:25 ET | 2095 | 0.4388 |
12:30 ET | 500 | 0.43 |
12:34 ET | 120 | 0.421 |
12:36 ET | 1000 | 0.435033 |
12:39 ET | 840 | 0.4388 |
12:50 ET | 200 | 0.42 |
12:54 ET | 200 | 0.438048 |
12:57 ET | 1450 | 0.4299 |
12:59 ET | 138 | 0.42 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
IGC Pharma Inc | 29.2M | -1.7x | --- |
Aprea Therapeutics Inc | 28.1M | -1.3x | --- |
Oncternal Therapeutics Inc | 25.3M | -0.7x | --- |
Surrozen Inc | 28.7M | -0.4x | --- |
Nymox Pharmaceutical Corp | 29.8M | -5.6x | --- |
Pluri Inc | 26.6M | -1.0x | --- |
IGC Pharma, Inc. is a clinical-stage pharmaceutical company. It develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer’s disease, period cramps, premenstrual syndrome, and chronic pain. Its segments include Life Sciences and Infrastructure. It has two investigational drug assets targeting Alzheimer’s disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer’s cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer’s disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol (THC) based formulation that is in a 146-person phase II clinical trial for agitation in dementia due to Alzheimer’s. TGR-63, a non-cannabinoid molecule, is an enzyme inhibitor shown in pre-clinical trials to reduce neurotoxicity in Alzheimer’s cell lines. It also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $29.2M |
---|---|
Revenue (TTM) | $1.2M |
Shares Outstanding | 66.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.72 |
EPS | $-0.25 |
Book Value | $0.28 |
P/E Ratio | -1.7x |
Price/Sales (TTM) | 24.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,175.16% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.